Why MongoDB Stock Is Moving Lower Friday
MongoDB, Inc. (NASDAQ: MDB) shares are trading lower Friday after the company issued weak guidance for the upcoming quarter as well as fiscal-year 2025.
Constellation Energy’s Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bearish stance on Constellation Energy. Looking…
What the Options Market Tells Us About Broadcom
Deep-pocketed investors have adopted a bullish approach towards Broadcom (NASDAQ:AVGO), and it’s something market players shouldn’t ignore. Our…
Airbus Battles Supply Chain Headwinds, Threatening Future Jet Deliveries: Report
Airbus is facing more difficulties in increasing jet production due to shortages of parts and labor. This may affect delivery targets but the company aims to produce 75 planes per month by 2026. Boeing is also facing production challenges and its stock prices are affected.
Market Whales and Their Recent Bets on VST Options
Deep-pocketed investors have adopted a bearish approach towards Vistra (NYSE:VST), and it’s something market players shouldn’t ignore. Our…
What’s Going On With Nikola Stock Friday?
The Russell 3000 index has begun its 2024 Reconstitution process, and Nikola Corporation is on the preliminary list of index deletions. If the deletion of Nikola proceeds, the company will be removed from the index as of the end of trading on June 28, 2024.
What’s Going On With Nvidia Stock On Friday?
Nvidia (NVDA) leads AI race with advanced chips, CEO Jensen Huang to speak at Taiwan's Computex event. US restricts AI chip exports to Middle East.
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a clinical collaboration.
What Celeb Meme Coins Could Mean For Bitcoin’s Price
Pseudonymous crypto trader Capo of Crypto recently identified an intriguing correlation about the appearance of celebrities in cryptocurrency markets and their connection to cycle tops.
Europe Approves Biogen’s Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.